BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Why are malnutrition deaths soaring in America? - 213 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- 3Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 4Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- 5New nesting beach for birds at RSPB reserve
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- Vote In favor of Your Favored Language Learning Applications
- IDF strikes Tehran command centers, weapon production sites
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- Best Wellness Tracker Keep You On target
